Biotest AG
OTC:BIESF
Biotest AG
OTC:BIESF
Price:
32
USD
Market Closed
Market Cap:
$1.3B
Balance Sheet
Balance Sheet Decomposition
Biotest AG
Biotest AG
Balance Sheet Decomposition is not available for
Biotest AG
Biotest AG
Balance Sheet
Biotest AG
Biotest AG
Currency: EUR
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
34
|
52
|
22
|
62
|
61
|
71
|
104
|
117
|
108
|
108
|
|
| Cash |
34
|
52
|
22
|
62
|
61
|
71
|
105
|
117
|
108
|
108
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
20
|
33
|
7
|
46
|
25
|
19
|
13
|
27
|
0
|
0
|
|
| Total Receivables |
307
|
180
|
145
|
164
|
151
|
167
|
151
|
164
|
205
|
201
|
|
| Accounts Receivables |
174
|
164
|
134
|
149
|
146
|
162
|
146
|
160
|
197
|
194
|
|
| Other Receivables |
133
|
16
|
12
|
15
|
5
|
5
|
4
|
4
|
8
|
7
|
|
| Inventory |
219
|
171
|
147
|
208
|
280
|
290
|
245
|
294
|
419
|
480
|
|
| Other Current Assets |
8
|
31
|
129
|
14
|
5
|
9
|
10
|
18
|
24
|
21
|
|
| Total Current Assets |
587
|
467
|
450
|
495
|
523
|
556
|
522
|
619
|
757
|
810
|
|
| PP&E Net |
317
|
415
|
477
|
513
|
548
|
548
|
550
|
548
|
578
|
571
|
|
| PP&E Gross |
317
|
415
|
477
|
513
|
548
|
548
|
550
|
548
|
578
|
571
|
|
| Accumulated Depreciation |
309
|
218
|
226
|
249
|
272
|
295
|
322
|
353
|
384
|
420
|
|
| Intangible Assets |
8
|
9
|
9
|
9
|
7
|
7
|
4
|
9
|
9
|
11
|
|
| Goodwill |
37
|
17
|
7
|
7
|
7
|
7
|
7
|
7
|
6
|
6
|
|
| Note Receivable |
1
|
0
|
7
|
7
|
7
|
0
|
6
|
13
|
17
|
15
|
|
| Long-Term Investments |
4
|
12
|
8
|
2
|
2
|
3
|
5
|
5
|
11
|
2
|
|
| Other Long-Term Assets |
10
|
13
|
20
|
9
|
14
|
10
|
11
|
1
|
33
|
20
|
|
| Other Assets |
37
|
17
|
7
|
7
|
7
|
7
|
7
|
7
|
6
|
6
|
|
| Total Assets |
963
N/A
|
933
-3%
|
979
+5%
|
1 042
+7%
|
1 108
+6%
|
1 131
+2%
|
1 104
-2%
|
1 203
+9%
|
1 411
+17%
|
1 434
+2%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
53
|
63
|
65
|
73
|
52
|
42
|
39
|
51
|
78
|
88
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
9
|
16
|
120
|
1
|
7
|
8
|
34
|
31
|
260
|
35
|
|
| Other Current Liabilities |
64
|
67
|
67
|
52
|
56
|
56
|
33
|
48
|
47
|
37
|
|
| Total Current Liabilities |
126
|
146
|
251
|
126
|
115
|
106
|
106
|
130
|
385
|
160
|
|
| Long-Term Debt |
336
|
330
|
287
|
329
|
402
|
461
|
495
|
613
|
430
|
636
|
|
| Deferred Income Tax |
8
|
3
|
3
|
3
|
1
|
1
|
2
|
1
|
1
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
81
|
94
|
90
|
90
|
113
|
122
|
120
|
88
|
96
|
106
|
|
| Total Liabilities |
551
N/A
|
572
+4%
|
631
+10%
|
547
-13%
|
632
+15%
|
690
+9%
|
724
+5%
|
832
+15%
|
912
+10%
|
903
-1%
|
|
| Equity | |||||||||||
| Common Stock |
40
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
|
| Retained Earnings |
116
|
64
|
58
|
240
|
221
|
185
|
154
|
112
|
250
|
275
|
|
| Additional Paid In Capital |
220
|
220
|
220
|
220
|
220
|
220
|
220
|
220
|
220
|
220
|
|
| Other Equity |
37
|
38
|
30
|
4
|
4
|
3
|
33
|
0
|
10
|
3
|
|
| Total Equity |
412
N/A
|
361
-13%
|
348
-4%
|
495
+42%
|
477
-4%
|
442
-7%
|
380
-14%
|
371
-2%
|
499
+34%
|
531
+6%
|
|
| Total Liabilities & Equity |
963
N/A
|
933
-3%
|
979
+5%
|
1 042
+7%
|
1 108
+6%
|
1 131
+2%
|
1 104
-2%
|
1 203
+9%
|
1 411
+17%
|
1 434
+2%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
20
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
40
|
|
| Preferred Shares Outstanding |
20
|
20
|
20
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
